Neal E. Ready, MD, PhD, Duke University Medical Center

Neal Edward Ready, MD, PhD, discusses factors to consider when deciding when the use the regimen of nivolumab and ipilimumab plus chemotherapy in metastatic non–small cell lung cancer.

Neal E. Ready, MD, PhD, discusses the role of frontline chemoimmunotherapy in lung cancer.

Neal E. Ready, MD, PhD, discusses selecting between frontline chemotherapy plus atezolizumab or durvalumab in extensive-stage small cell lung cancer.

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses emerging treatment approaches in small cell lung cancer (SCLC).

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses the benefit of PD-L1 inhibition in small cell lung cancer.